FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2398577733> ?p ?o ?g. }

• W2398577733 abstract "Background: TNBC often exhibits activation of PI3K/Akt signaling, associated with loss of PTEN expression, low INPP4B expression, and/or increased AKT3 amplification. Inhibition of the PI3K/Akt pathway in diverse cancers leads to radiosensitization and/or chemosensitization. Ipat is an oral, potent ATP-competitive small molecule inhibitor of all three isoforms of Akt. The combination of ipat with taxanes in preclinical models resulted in enhanced efficacy relative to either ipat or chemotherapy alone. In a Phase Ib clinical study, the combination of ipat with diverse chemotherapy regimens was well-tolerated and resulted in RECIST responses, particularly pts with tumors having PI3K/Akt activation. Methods: FAIRLANE is a randomized, double-blind, placebo controlled, multicenter, neoadjuvant Phase II study designed to estimate the efficacy of ipat combined with pac versus placebo combined with pac in women with Stage Ia  IIIa TNBC. Approximately 150 pts (Pts) will be enrolled, randomized in a 1:1 ratio, and stratified by PTEN status, node involvement, and tumor size. Pts will receive 3 cycles of ipat 400 mg or placebo orally once daily on Days 1 to 21 of each 28-day cycle, along with pac 80 mg/m2 every 7 days for a total of 12 doses. All pts will undergo pretreatment and Day 8 tumor tissue acquisition to evaluate pathway biomarkers. Following three cycles of treatment, pts will undergo surgery. The primary efficacy endpoint, pCR within the breast and axilla (ypT0/Tis ypN0) in all pts and in pts with PTEN low tumors, will be assessed by local pathology evaluation following completion of neoadjuvant therapy and surgery. Additional endpoints include objective response rate, safety, BCS rate, pharmacokinetics, and pathway biomarkers. Following surgical resection of primary tumor, pts are expected to continue post-operative treatment with a standard adjuvant chemotherapy regimen at physician9s discretion. The study is open for accrual. Clinical trial information: NCT02301988. Citation Format: Saura C, Isakoff SJ, Calvo I, Patt D, Andersen J, Gonzalez-Martin A, Fisher J, Ciruelos E, Gil-Gil M, De la Pena L, Choi Y, Jia S, Singel S, Patel PH, Baselga J, Oliveira M. FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT1-03-09." @default.
• W2398577733 created "2016-06-24" @default.
• W2398577733 creator A5020050040 @default.
• W2398577733 creator A5026031341 @default.
• W2398577733 creator A5032379353 @default.
• W2398577733 creator A5035539008 @default.
• W2398577733 creator A5036940239 @default.
• W2398577733 creator A5040489877 @default.
• W2398577733 creator A5050590164 @default.
• W2398577733 creator A5052647340 @default.
• W2398577733 creator A5056181342 @default.
• W2398577733 creator A5057580348 @default.
• W2398577733 creator A5062647643 @default.
• W2398577733 creator A5072306573 @default.
• W2398577733 creator A5077979726 @default.
• W2398577733 creator A5081099575 @default.
• W2398577733 creator A5082195410 @default.
• W2398577733 creator A5088119887 @default.
• W2398577733 date "2016-02-15" @default.
• W2398577733 modified "2023-10-18" @default.
• W2398577733 title "Abstract OT1-03-09: FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC)" @default.
• W2398577733 doi "https://doi.org/10.1158/1538-7445.sabcs15-ot1-03-09" @default.
• W2398577733 hasPublicationYear "2016" @default.
• W2398577733 type Work @default.
• W2398577733 sameAs 2398577733 @default.
• W2398577733 citedByCount "1" @default.
• W2398577733 countsByYear W23985777332018 @default.
• W2398577733 crossrefType "proceedings-article" @default.
• W2398577733 hasAuthorship W2398577733A5020050040 @default.
• W2398577733 hasAuthorship W2398577733A5026031341 @default.
• W2398577733 hasAuthorship W2398577733A5032379353 @default.
• W2398577733 hasAuthorship W2398577733A5035539008 @default.
• W2398577733 hasAuthorship W2398577733A5036940239 @default.
• W2398577733 hasAuthorship W2398577733A5040489877 @default.
• W2398577733 hasAuthorship W2398577733A5050590164 @default.
• W2398577733 hasAuthorship W2398577733A5052647340 @default.
• W2398577733 hasAuthorship W2398577733A5056181342 @default.
• W2398577733 hasAuthorship W2398577733A5057580348 @default.
• W2398577733 hasAuthorship W2398577733A5062647643 @default.
• W2398577733 hasAuthorship W2398577733A5072306573 @default.
• W2398577733 hasAuthorship W2398577733A5077979726 @default.
• W2398577733 hasAuthorship W2398577733A5081099575 @default.
• W2398577733 hasAuthorship W2398577733A5082195410 @default.
• W2398577733 hasAuthorship W2398577733A5088119887 @default.
• W2398577733 hasConcept C121608353 @default.
• W2398577733 hasConcept C126322002 @default.
• W2398577733 hasConcept C142724271 @default.
• W2398577733 hasConcept C143998085 @default.
• W2398577733 hasConcept C185592680 @default.
• W2398577733 hasConcept C190283241 @default.
• W2398577733 hasConcept C203092338 @default.
• W2398577733 hasConcept C204787440 @default.
• W2398577733 hasConcept C27081682 @default.
• W2398577733 hasConcept C2776694085 @default.
• W2398577733 hasConcept C2777609662 @default.
• W2398577733 hasConcept C2778292576 @default.
• W2398577733 hasConcept C31760486 @default.
• W2398577733 hasConcept C530470458 @default.
• W2398577733 hasConcept C535046627 @default.
• W2398577733 hasConcept C55493867 @default.
• W2398577733 hasConcept C71924100 @default.
• W2398577733 hasConcept C75217442 @default.
• W2398577733 hasConcept C86554907 @default.
• W2398577733 hasConcept C98274493 @default.
• W2398577733 hasConceptScore W2398577733C121608353 @default.
• W2398577733 hasConceptScore W2398577733C126322002 @default.
• W2398577733 hasConceptScore W2398577733C142724271 @default.
• W2398577733 hasConceptScore W2398577733C143998085 @default.
• W2398577733 hasConceptScore W2398577733C185592680 @default.
• W2398577733 hasConceptScore W2398577733C190283241 @default.
• W2398577733 hasConceptScore W2398577733C203092338 @default.
• W2398577733 hasConceptScore W2398577733C204787440 @default.
• W2398577733 hasConceptScore W2398577733C27081682 @default.
• W2398577733 hasConceptScore W2398577733C2776694085 @default.
• W2398577733 hasConceptScore W2398577733C2777609662 @default.
• W2398577733 hasConceptScore W2398577733C2778292576 @default.
• W2398577733 hasConceptScore W2398577733C31760486 @default.
• W2398577733 hasConceptScore W2398577733C530470458 @default.
• W2398577733 hasConceptScore W2398577733C535046627 @default.
• W2398577733 hasConceptScore W2398577733C55493867 @default.
• W2398577733 hasConceptScore W2398577733C71924100 @default.
• W2398577733 hasConceptScore W2398577733C75217442 @default.
• W2398577733 hasConceptScore W2398577733C86554907 @default.
• W2398577733 hasConceptScore W2398577733C98274493 @default.
• W2398577733 hasLocation W23985777331 @default.
• W2398577733 hasOpenAccess W2398577733 @default.
• W2398577733 hasPrimaryLocation W23985777331 @default.
• W2398577733 hasRelatedWork W1051628 @default.
• W2398577733 hasRelatedWork W13328401 @default.
• W2398577733 hasRelatedWork W14057612 @default.
• W2398577733 hasRelatedWork W14328058 @default.
• W2398577733 hasRelatedWork W14561912 @default.
• W2398577733 hasRelatedWork W18725558 @default.
• W2398577733 hasRelatedWork W2422317 @default.
• W2398577733 hasRelatedWork W5038423 @default.
• W2398577733 hasRelatedWork W9309986 @default.
• W2398577733 hasRelatedWork W12384393 @default.
• W2398577733 isParatext "false" @default.
• W2398577733 isRetracted "false" @default.
• W2398577733 magId "2398577733" @default.

• next